Beta Bionics, Inc. (BBNX) News
Follow Beta Bionics, Inc. (BBNX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 35 public stories across 16 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Beta Bionics Sued for Securities Fraud After Medical Device Safety Issues
The headline reports a securities-fraud lawsuit against Beta Bionics following medical device safety issues. It also says the stock dropped 37%.
REGULATION | Oct 28, 2026, 10:38 AM UTC
M
BBNX Reports Fiscal Q3 Net Loss
BBNX reported a fiscal third-quarter net loss attributable to shareholders, down 16.6% year over year. Basic EPS was negative.
EQUITY | Oct 28, 2026, 05:21 AM UTC
M
Beta Bionics Expects MINT to Recapture Any Q4 2026 Revenue Loss in 2027
Beta Bionics expects MINT to recapture during full-year 2027 any revenue lost in the fourth quarter of 2026.
EQUITY | Oct 27, 2026, 08:39 PM UTC
M
Beta Bionics Forecasts FY Revenue of $124–126 Million
EARNINGS | Oct 27, 2026, 08:39 PM UTC
M
Beta Bionics Reports 3Q Loss of $24.4M
EARNINGS | Oct 27, 2026, 08:31 PM UTC
M
Beta Bionics Reports Q3 Adjusted EBITDA
Beta Bionics reported Q3 adjusted EBITDA, versus an IBES estimate.
EARNINGS | Oct 27, 2026, 08:16 PM UTC
M
Beta Bionics Reports Q3 Gross Profit of USD 20.331 Million
EQUITY | Oct 27, 2026, 08:06 PM UTC
L
Beta Bionics Reports Q3 EPS of USD -0.52
EARNINGS | Oct 27, 2026, 08:06 PM UTC
M
Beta Bionics Reports Third-Quarter Results, Updates 2026 Guidance
Beta Bionics reported results for the quarter ended September 30, 2026, and updated its full-year 2026 guidance.
EQUITY | Oct 27, 2026, 08:04 PM UTC
H
Beta Bionics Stock Falls 37% on Safety Issues, Class Action Filed
Beta Bionics' stock experienced a significant decline of 37% following disclosures of medical device safety issues. A securities fraud class action has also been filed against the company.
EQUITY | Oct 06, 2026, 09:36 AM UTC
L
Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. NASDAQ:BBNX, a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quar
EARNINGS | Sep 29, 2026, 12:09 PM UTC
M
Beta Bionics to announce Q3 2026 financial results on Oct 27, 2026
EQUITY | Sep 29, 2026, 12:01 PM UTC
L
Weekly Recap: iLet AID with Eversense 365 and Wells Fargo $28 PT
Beta Bionics, Inc. (NASDAQ:BBNX) plans to integrate its iLet AID with Senseonics’ Eversense 365 CGM aiming for a commercial launch in Q4 2026, with Mint to follow, as Wells Fargo initiated coverage and set a $28 price ta
NEWS | Sep 28, 2026, 11:05 AM UTC
L
Beta Bionics Price Target Raised to $28.00/Share From $23.00 by Truist Securities
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 03:50 PM UTC
L
Beta Bionics Price Target Announced at $28.00/Share by Wells Fargo
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 03:39 PM UTC
M
Beta Bionics to integrate iLet and mint with Senseonics’ Eversense 365
Beta Bionics said it has announced an agreement to integrate its iLet Bionic Pancreas and mint automated insulin delivery systems with Senseonics’ Eversense 365.
EQUITY | Sep 22, 2026, 11:33 AM UTC
L
BBNX - Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
BBNX - Beta Bionics Announces Agreement Integrate the iLet® Bionic Pancreas and mint™ with Senseonics’ Eversense® 365
NEWS | Sep 22, 2026, 11:30 AM UTC
M
Beta Bionics receives FDA clearance for Mint patch pump
Beta Bionics says its Mint patch pump received FDA clearance, it filed its 3D dosing algorithm, and it formed a Senseonics Eversense 365 CGM partnership. The company trimmed 2026 revenue guidance to $121–$126M and raised
EQUITY | Sep 21, 2026, 11:29 AM UTC
M
Beta Bionics closes $172.5 million public stock offering
Beta Bionics said it closed its previously announced underwritten public offering of 7,652,175 shares at $17.25 per share.
EQUITY | Sep 17, 2026, 08:11 PM UTC
M
Beta prices $150 million upsized stock offering at $17.25
Beta Bionics priced an underwritten offering expected to raise about $150 million through common stock and pre-funded warrants.
EQUITY | Sep 17, 2026, 10:03 AM UTC
H
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Nasdaq Composite gaining around 150 points on Wednesday. Shares of LuxExperience BV-ADR (NYSE: LUXE ) rose sharply after the company reported fourth-quarter results. LuxExperience reporte
LIVE | Sep 16, 2026, 01:57 PM UTC
M
Beta Bionics shares slide after pricing underwritten public offering
Beta Bionics priced an underwritten public offering, and the stock fell 5.8% to $18.11 in premarket trading Wednesday after being down 37% for the year at Tuesday’s close.
EQUITY | Sep 16, 2026, 11:09 AM UTC
H
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Shares of Tempest Therapeutics Inc (NASDAQ: TPST ) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnolo
LIVE | Sep 16, 2026, 09:04 AM UTC
L
BBNX - Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
BBNX - Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
EQUITY | Sep 16, 2026, 04:08 AM UTC
M
Beta Bionics proposes $125 million underwritten public offering
Beta Bionics proposed a $125 million underwritten public offering. BBNX shares slipped 5.1% to $18.25 in after-hours Tuesday.
EQUITY | Sep 15, 2026, 09:05 PM UTC
M
Beta Bionics gets FDA clearance for Mint patch pump
Beta Bionics said the FDA cleared Mint, its rechargeable-free patch pump, and that it submitted a 510(k) for 3D Intelligence.
REGULATION | Sep 15, 2026, 09:04 PM UTC
L
BBNX - Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock
BBNX - Beta Bionics Announces Proposed Public Offering of $125.0 Million of Common Stock
EQUITY | Sep 15, 2026, 08:22 PM UTC
L
Beta Bionics Price Target Raised to $23.00/Share From $22.00 by Truist Securities
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 03:01 PM UTC
L
Beta Bionics Price Target Raised to $16.00/Share From $14.00 by Baird
Ratings actions from Benzinga: GMT) Beta Bionics Is Maintained at Neutral by BairdRatings actions from Benzinga
NEWS | Sep 15, 2026, 12:52 PM UTC
L
Beta Bionics Is Maintained at Outperform by Leerink Partners
Ratings actions from Benzinga
NEWS | Sep 14, 2026, 10:11 PM UTC
M
Beta Bionics wins FDA clearance for Mint pump
Beta Bionics said the FDA cleared its Mint pump, which does not require recharging and integrates with continuous glucose monitors. The company also lowered full-year 2026 sales guidance to $121 million-$126 million from
EQUITY | Sep 14, 2026, 11:36 AM UTC
L
William Blair initiates BBNX at Market Perform
William Blair initiates BBNX with a Market Perform rating; no price target or catalyst was supplied in the alert.
EQUITY | Aug 21, 2026, 11:58 AM UTC
H
BBNX: Stifel Maintains Buy
Stifel maintains buy rating on BBNX
EQUITY | Jul 30, 2026, 11:36 AM UTC
L
Beta Bionics Affirms FY2026 Sales Guidance of $131.000M-$136.000M vs $133.305M Est
Beta Bionics (NASDAQ: BBNX ) affirms FY2026 sales outlook from $131.000 million-$136.000 million to $131.000 million-$136.000 million vs $133.305 million estimate.
EARNINGS | Jul 29, 2026, 08:03 PM UTC
L
BBNX - Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
BBNX - Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
EARNINGS | Jul 29, 2026, 08:02 PM UTC